Modality
Small Molecule
MOA
PD-1i
Target
PD-1
Pathway
Complement
Fabry
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
~Mar 2017
→ ~Jun 2018
Phase 2
~Sep 2018
→ ~Dec 2019
Phase 3
~Mar 2020
→ ~Jun 2021
NDA/BLA
Sep 2021
→ May 2029
NDA/BLACurrent
NCT04382007
2,187 pts·Fabry
2021-09→2029-05·Recruiting
2,187 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-05-103.1y awayPh3 Readout· Fabry
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2029-05-10 · 3.1y away
Fabry
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04382007 | NDA/BLA | Fabry | Recruiting | 2187 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Motanaritide | Intellia | Approved | PD-1 | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R |